Pharmaceutical

Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection Company shifts focus to phase 3 VE303 trial in recurrent C. difficile...

Project aims to improve global immunisation through needle-free delivery Project aims to improve global immunisation through needle-free delivery

Merck’s therapy becomes first authorised option for aggressive soft tissue tumours Merck’s therapy becomes first authorised option for aggressive soft...

Every year, Fierce celebrates women making a powerful impact across biopharma and medtech. It’s time once again to make your suggestions for this year...

Discover how Fedegari’s FOB5 is redefining sterilization with compact design, GMP compliance & high-containment capabilities.

Robin Marcus shares how Marken is expanding patient access, supporting trial sites and driving breakthroughs in decentralized research.

Key cancer drugs lose exclusivity soon—who’s ready to withstand the oncology patent cliff?

A new wave of Alzheimer’s research suggests semaglutide, widely known for diabetes and weight loss, could also slow cognitive decline—two major trials...

The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a c...

The FDA has approved a treatment for recurrent respiratory papillomatosis for the first time. The agency has signed off on Precigen’s Papzimeos, a non...